Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.07 -4.4%	$19.18	$14.23 ▼ $30.41	$1.90B	0.92	1.98 million shs	1.19 million shs
EXAI Exscientia	$4.84 +3.2%	$4.97	$3.80 ▼ $6.88	$632.93M	0.83	641,401 shs	1.51 million shs
HCM HUTCHMED	$15.37 -0.8%	$14.66	$12.84 ▼ $21.92	$2.68B	0.77	86,018 shs	39,643 shs
IBRX ImmunityBio	$2.90 +1.0%	$3.07	$2.28 ▼ $10.53	$2.47B	0.82	6.17 million shs	4.25 million shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-4.44%	-14.71%	-20.22%	-31.03%	-47.29%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	-28.61%
HCM HUTCHMED	-0.77%	-4.06%	+16.44%	-1.35%	-17.19%
IBRX ImmunityBio	+1.05%	-3.01%	-8.52%	+1.05%	-42.91%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6995 of 5 stars	3.3	2.0	3.4	2.8	2.5	0.0
EXAI Exscientia	0.6866 of 5 stars	2.0	0.0	0.0	0.6	1.7	0.6
HCM HUTCHMED	1.8968 of 5 stars	2.0	4.0	0.0	2.6	0.0	1.9
IBRX ImmunityBio	2.0129 of 5 stars	3.5	1.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.60	Moderate Buy	$41.44	175.01% Upside
EXAI Exscientia	2.00	Hold	$6.00	23.97% Upside
HCM HUTCHMED	2.00	Hold	$19.00	23.62% Upside
IBRX ImmunityBio	3.00	Buy	$12.19	320.26% Upside

Current Analyst Ratings Breakdown

Latest EXAI, IBRX, ARWR, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/13/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/13/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/6/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
2/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
2/14/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$51.00 ➝ $38.00
2/14/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
2/12/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
2/11/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$42.00 ➝ $42.00
2/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
1/27/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
1/23/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$2.50M	760.12	N/A	N/A	$1.54 per share	9.79
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
HCM HUTCHMED	$610.81M	4.39	$0.63 per share	24.51	$4.27 per share	3.60
IBRX ImmunityBio	$14.75M	167.85	N/A	N/A	($0.88) per share	-3.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$5.17	N/A	N/A	N/A	N/A	-236.60%	-64.09%	5/8/2025 (Estimated)
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
HCM HUTCHMED	$100.78M	N/A	0.00	10.53	N/A	N/A	N/A	N/A	3/19/2025 (Estimated)
IBRX ImmunityBio	-$583.20M	-$0.63	N/A	N/A	N/A	-8,016.83%	N/A	-110.02%	3/18/2025 (Estimated)

Latest EXAI, IBRX, ARWR, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/18/2025	N/A	IBRX ImmunityBio	-$0.26	N/A	N/A	N/A	$9.51 million	N/A
3/3/2025	Q4 2024	IBRX ImmunityBio	-$0.26	-$0.15	+$0.11	-$0.09	$8.74 million	$7.55 million
2/10/2025	Q1 2025	ARWR Arrowhead Pharmaceuticals	-$0.42	-$1.39	-$0.97	-$1.39	$19.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
EXAI Exscientia	0.06	4.54	4.54
HCM HUTCHMED	0.07	2.81	2.68
IBRX ImmunityBio	N/A	2.68	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
EXAI Exscientia	41.58%
HCM HUTCHMED	8.82%
IBRX ImmunityBio	8.58%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
EXAI Exscientia	16.40%
HCM HUTCHMED	3.60%
IBRX ImmunityBio	83.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	126.10 million	120.68 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
HCM HUTCHMED	1,988	174.32 million	168.04 million	Not Optionable
IBRX ImmunityBio	590	853.44 million	115.67 million	Optionable

EXAI, IBRX, ARWR, and HCM Headlines

Recent News About These Companies

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

March 13 at 9:45 PM | urotoday.com

ImmunityBio announces 1st dosing of rBCG in U.S. and 60 sites pending

March 13 at 9:45 PM | markets.businessinsider.com

ImmunityBio, Inc. (IBRX): Among the Stocks Under $10 With High Upside Potential

March 12 at 9:59 PM | insidermonkey.com

ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

March 11 at 3:08 AM | marketbeat.com

Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright

March 11 at 1:32 AM | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Research Coverage Started at HC Wainwright

March 9, 2025 | americanbankingnews.com

ImmunityBio (NASDAQ:IBRX) Coverage Initiated by Analysts at HC Wainwright

March 7, 2025 | marketbeat.com

How ImmunityBio, Inc. (NASDAQ:IBRX) Is Navigating Market Trends and Institutional Shifts

March 7, 2025 | kalkinemedia.com

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

March 7, 2025 | seekingalpha.com

ImmunityBio initiated with a Buy at H.C. Wainwright

March 6, 2025 | markets.businessinsider.com

ImmunityBio (NASDAQ:IBRX) Trading 6.8% Higher After Better-Than-Expected Earnings

March 6, 2025 | americanbankingnews.com

ImmunityBio (NASDAQ:IBRX) Trading Up 6.8% on Strong Earnings

March 5, 2025 | marketbeat.com

Why ImmunityBio Inc. (IBRX) Crashed on Monday

March 4, 2025 | msn.com

ImmunityBio stock rises on Q4 earnings beat, revenue growth

March 4, 2025 | investing.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Should You Sell?

March 3, 2025 | marketbeat.com

ImmunityBio reports Q4 EPS (9c), consensus (13c)

March 3, 2025 | markets.businessinsider.com

ImmunityBio: Q4 Earnings Snapshot

March 3, 2025 | finance.yahoo.com

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates

March 3, 2025 | zacks.com

ImmunityBio (NASDAQ:IBRX) Announces Earnings Results, Beats Estimates By $0.11 EPS

March 3, 2025 | marketbeat.com

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

March 3, 2025 | businesswire.com

Why ImmunityBio, Inc.’s (IBRX) Stock Is Up 15.03%

March 2, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXAI, IBRX, ARWR, and HCM Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.07 -0.70 (-4.44%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$15.06 -0.02 (-0.10%)

As of 03/13/2025 07:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

HUTCHMED NASDAQ:HCM

$15.37 -0.12 (-0.77%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$15.38 +0.01 (+0.03%)

As of 03/13/2025 04:05 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

ImmunityBio NASDAQ:IBRX

$2.90 +0.03 (+1.05%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$2.91 +0.01 (+0.31%)

As of 03/13/2025 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time